Radiolabeled immunoglobulin therapy in patients with Hodgkin's disease

Translational research supports the use of radiolabeled antiferritin for re current Hodgkin's disease. A 60% tumor response rate is obtained after trea tment of out-patients with polyclonal radiolabeled antiferritin, Hodgkin's disease masses shrink after radiolabeled antiferritin treatment due to the radiation delivered by the radioimmunoconjugate. Unlabeled antiferritin doe s not cause tumor shrinkage. Hodgkin's disease provides unique opportunitie s for the development and optimization of radiolabeled immunoglobulin thera py for other malignancies as well. Radiolabeled Immunoglobulin Therapy is a useful addition to the cancer trea tment armamentarium due to its high therapeutic ratio: high tumor response rates with side effects limited to hematopoetic tissues.